[Form 4] Becton, Dickinson and Co. Insider Trading Activity
Michael Feld, EVP & President, Life Sciences at Becton, Dickinson and Company (BDX), reported a non-derivative disposition of 773 shares of BDX common stock on 08/20/2025. The filing uses transaction code F, and the explanatory note states these shares were withheld to satisfy tax withholding upon vesting of previously granted restricted stock units, so the reported price is shown as $0. After the withholding, Mr. Feld beneficially owned 8,417 shares directly. The Form 4 was signed by Donna Kalazdy by power of attorney on 08/22/2025.
Michael Feld, EVP e Presidente, Life Sciences di Becton, Dickinson and Company (BDX), ha riportato una cessione non derivativa di 773 azioni ordinarie BDX in data 20/08/2025. La segnalazione utilizza il codice transazione F e la nota esplicativa specifica che le azioni sono state trattenute per soddisfare le imposte alla scadenza di restricted stock units precedentemente concesse, pertanto il prezzo indicato è $0. Dopo la ritenuta, il Sig. Feld possedeva direttamente beneficiamente 8.417 azioni. Il Modulo 4 è stato firmato da Donna Kalazdy per procura in data 22/08/2025.
Michael Feld, EVP y Presidente de Life Sciences en Becton, Dickinson and Company (BDX), informó una disposición no derivativa de 773 acciones ordinarias de BDX el 20/08/2025. La presentación utiliza el código de transacción F y la nota explicativa indica que dichas acciones fueron retenidas para cubrir las retenciones fiscales al consolidarse unidades restringidas de acciones previamente otorgadas, por lo que el precio informado aparece como $0. Tras la retención, el Sr. Feld poseía beneficiariamente 8.417 acciones en propiedad directa. El Formulario 4 fue firmado por Donna Kalazdy por poder el 22/08/2025.
Michael Feld, Becton, Dickinson and Company(BDX)에서 Life Sciences 담당 EVP 겸 사장, 은 2025-08-20에 BDX 보통주 773주의 비파생 처분을 보고했습니다. 신고서에는 거래 코드 F가 사용되었고 설명란에는 이 주식들이 기존에 부여된 제한주(RSU)의 확정 시 세금 원천징수를 충족하기 위해 원천징수되었다고 기재되어 있어 보고된 가격은 $0로 표시됩니다. 원천징수 후 Feld 씨는 직접적으로 8,417주를 실소유하고 있었습니다. Form 4는 2025-08-22에 Donna Kalazdy가 위임장으로 서명했습니다.
Michael Feld, EVP et Président, Life Sciences chez Becton, Dickinson and Company (BDX), a déclaré une cession non dérivative de 773 actions ordinaires BDX le 20/08/2025. Le dépôt utilise le code de transaction F et la note explicative précise que ces actions ont été retenues pour couvrir les impôts dus lors de la levée d'unités d'actions restreintes précédemment attribuées, d'où le prix déclaré de 0 $. Après cette retenue, M. Feld détenait bénéficiairement 8 417 actions en propriété directe. Le formulaire 4 a été signé par Donna Kalazdy par procuration le 22/08/2025.
Michael Feld, EVP und President, Life Sciences bei Becton, Dickinson and Company (BDX), meldete am 20.08.2025 eine nicht-derivative Veräußerung von 773 Aktien der BDX-Stammaktien. Die Meldung verwendet den Transaktionscode F und der erläuternde Hinweis besagt, dass diese Aktien zur Begleichung der Steuerabzüge beim Vesting zuvor gewährter Restricted Stock Units einbehalten wurden, weshalb der gemeldete Preis mit $0 angegeben ist. Nach dem Einbehalt hielt Herr Feld direkt wirtschaftlich 8.417 Aktien. Das Formular 4 wurde am 22.08.2025 von Donna Kalazdy per Vollmacht unterschrieben.
- None.
- None.
Insights
TL;DR Insider withheld 773 shares for taxes after RSU vesting; small, routine change in holdings.
This Form 4 documents a tax-withholding disposition tied to vesting of previously reported restricted stock units, not an open-market sale or new compensation grant. The reduction of 773 shares to a post-transaction balance of 8,417 shares represents a routine settlement activity that does not change the executive's economic exposure meaningfully. There are no cash proceeds reported and no derivative activity disclosed.
TL;DR Filing reflects standard compliance with Section 16 reporting for RSU tax withholding.
The disclosure is consistent with standard equity compensation practices and shows timely reporting with a power-of-attorney signature. Because the transaction was a withholding for tax obligations, it does not indicate discretionary insider selling or a change in governance. No material governance or control implications are evident from the information provided.
Michael Feld, EVP e Presidente, Life Sciences di Becton, Dickinson and Company (BDX), ha riportato una cessione non derivativa di 773 azioni ordinarie BDX in data 20/08/2025. La segnalazione utilizza il codice transazione F e la nota esplicativa specifica che le azioni sono state trattenute per soddisfare le imposte alla scadenza di restricted stock units precedentemente concesse, pertanto il prezzo indicato è $0. Dopo la ritenuta, il Sig. Feld possedeva direttamente beneficiamente 8.417 azioni. Il Modulo 4 è stato firmato da Donna Kalazdy per procura in data 22/08/2025.
Michael Feld, EVP y Presidente de Life Sciences en Becton, Dickinson and Company (BDX), informó una disposición no derivativa de 773 acciones ordinarias de BDX el 20/08/2025. La presentación utiliza el código de transacción F y la nota explicativa indica que dichas acciones fueron retenidas para cubrir las retenciones fiscales al consolidarse unidades restringidas de acciones previamente otorgadas, por lo que el precio informado aparece como $0. Tras la retención, el Sr. Feld poseía beneficiariamente 8.417 acciones en propiedad directa. El Formulario 4 fue firmado por Donna Kalazdy por poder el 22/08/2025.
Michael Feld, Becton, Dickinson and Company(BDX)에서 Life Sciences 담당 EVP 겸 사장, 은 2025-08-20에 BDX 보통주 773주의 비파생 처분을 보고했습니다. 신고서에는 거래 코드 F가 사용되었고 설명란에는 이 주식들이 기존에 부여된 제한주(RSU)의 확정 시 세금 원천징수를 충족하기 위해 원천징수되었다고 기재되어 있어 보고된 가격은 $0로 표시됩니다. 원천징수 후 Feld 씨는 직접적으로 8,417주를 실소유하고 있었습니다. Form 4는 2025-08-22에 Donna Kalazdy가 위임장으로 서명했습니다.
Michael Feld, EVP et Président, Life Sciences chez Becton, Dickinson and Company (BDX), a déclaré une cession non dérivative de 773 actions ordinaires BDX le 20/08/2025. Le dépôt utilise le code de transaction F et la note explicative précise que ces actions ont été retenues pour couvrir les impôts dus lors de la levée d'unités d'actions restreintes précédemment attribuées, d'où le prix déclaré de 0 $. Après cette retenue, M. Feld détenait bénéficiairement 8 417 actions en propriété directe. Le formulaire 4 a été signé par Donna Kalazdy par procuration le 22/08/2025.
Michael Feld, EVP und President, Life Sciences bei Becton, Dickinson and Company (BDX), meldete am 20.08.2025 eine nicht-derivative Veräußerung von 773 Aktien der BDX-Stammaktien. Die Meldung verwendet den Transaktionscode F und der erläuternde Hinweis besagt, dass diese Aktien zur Begleichung der Steuerabzüge beim Vesting zuvor gewährter Restricted Stock Units einbehalten wurden, weshalb der gemeldete Preis mit $0 angegeben ist. Nach dem Einbehalt hielt Herr Feld direkt wirtschaftlich 8.417 Aktien. Das Formular 4 wurde am 22.08.2025 von Donna Kalazdy per Vollmacht unterschrieben.